PPP1R12A Antibody

What is PPP1R12A and what are its key biological functions?

PPP1R12A (Protein phosphatase 1 regulatory subunit 12A) is a regulatory enzyme subunit that interacts with protein phosphatase type 1 catalytic unit (PP1C) and M20/21 to form the trimeric holoenzyme called myosin phosphatase (MP) . This complex serves as a key regulator of cell morphology and motility through its control of protein phosphorylation status . PPP1R12A specifically regulates PP1 function in smooth muscle relaxation pathways, making it critical for vascular and other smooth muscle functions .

The protein is predominantly expressed in striated muscles, specifically in type 2a fibers, although its expression is not limited to muscle tissue . Recent research has identified PPP1R12A as part of a previously undescribed tumor suppressor cascade that includes the protein merlin . This pathway can be compromised either through mutation of the NF2 gene or by upregulation of the oncoprotein CPI17, which functions as a cellular MYPT1-PP1-delta-specific inhibitor .

What are the common synonyms and identifiers for PPP1R12A?

PPP1R12A is known by several alternative names in the scientific literature, which can sometimes create confusion when searching for information. The following table provides a comprehensive list of identifiers and synonyms:

Researchers should be aware of these various nomenclatures when conducting literature searches to ensure comprehensive coverage of relevant studies .

What is the molecular structure and cellular localization of PPP1R12A?

PPP1R12A is a cytoplasmic protein with a molecular mass of approximately 115.3 kDa in its canonical form . The human protein consists of 1,030 amino acid residues and has been reported to exist in up to five different isoforms resulting from alternative splicing . The gene encoding PPP1R12A is located on chromosome 12q21.2-q21.3 .

The protein contains several important functional domains that facilitate its regulatory activities, including regions for PP1C binding and sites for post-translational modifications, particularly phosphorylation . These phosphorylation sites are critical for regulating the activity of the myosin phosphatase complex, with phosphorylation at specific residues such as Thr696, Thr853, and Ser507 having significant impacts on enzyme function .

The subcellular localization of PPP1R12A is primarily cytoplasmic, where it can interact with its binding partners to form the functional myosin phosphatase complex . This localization is consistent with its role in regulating cytoskeletal dynamics and cell motility.

How do I select the appropriate PPP1R12A antibody for my specific research application?

Selecting the appropriate PPP1R12A antibody requires careful consideration of several factors based on your experimental goals. First, determine which specific epitope or phosphorylation site you need to target. Various antibodies are available that recognize different regions of PPP1R12A including N-terminal (AA 1-40), mid-region (AA 481-514), and C-terminal (CREDEYKQKYSRTYD) epitopes . For phosphorylation studies, specific antibodies targeting pThr696, pThr853, or pSer507 are available .

Consider the species reactivity required for your research. Most commercially available antibodies recognize human PPP1R12A, but many also cross-react with mouse and rat orthologs . Confirm the species reactivity in the product documentation before proceeding.

The application compatibility is another crucial factor. Different antibodies perform optimally in specific applications:

• For Western blotting: Most antibodies perform well, but validation in your specific system is recommended

• For immunofluorescence: Select antibodies specifically validated for IF such as those demonstrating cytoplasmic localization in cell lines like A431

• For immunohistochemistry: Choose antibodies specifically tested for IHC-P applications

• For flow cytometry: Select antibodies validated for FACS applications

Finally, consider the antibody format (polyclonal vs. monoclonal) based on your need for specificity versus broader epitope recognition. Polyclonal antibodies often provide stronger signals but may have increased background, while monoclonals offer higher specificity for a single epitope .

What validation steps should I perform when using a new PPP1R12A antibody?

When introducing a new PPP1R12A antibody to your research workflow, comprehensive validation is essential to ensure reliable and reproducible results. Begin with positive and negative controls—use tissue or cell lines known to express PPP1R12A (such as striated muscle samples or A431 cells) as positive controls . For negative controls, employ either tissues known to lack PPP1R12A expression or use primary antibody omission controls.

Perform specificity testing through peptide competition assays. Pre-incubating the antibody with the immunizing peptide should abolish specific staining in applications like Western blot, immunofluorescence, or immunohistochemistry . This confirms the antibody is binding to its intended target.

Validation across multiple applications is also recommended. If your primary application is Western blotting, verify that the antibody detects a band of approximately 115.3 kDa, consistent with the expected molecular weight of PPP1R12A . For phospho-specific antibodies, treatment with phosphatases should eliminate signal, while treatments that enhance phosphorylation (like calyculin A for certain sites) should increase signal .

For immunofluorescence or immunohistochemistry, confirm the expected cytoplasmic localization pattern as observed in validated studies . Compare your staining pattern with published literature to ensure consistency in localization and expression patterns.

Finally, validate isoform recognition if relevant to your research. Since PPP1R12A has up to five reported isoforms, determine whether your antibody recognizes all isoforms or preferentially binds specific variants . This information is crucial for accurate interpretation of your results, especially in tissues or cell lines where multiple isoforms may be expressed.

How can I troubleshoot non-specific binding or weak signals when using PPP1R12A antibodies?

Non-specific binding and weak signals are common challenges when working with PPP1R12A antibodies. For non-specific binding in Western blots, optimize blocking conditions by testing different blocking agents (BSA, milk, commercial blockers) and concentrations (3-5%) . Increasing the stringency of wash steps with higher salt concentrations (up to 500 mM NaCl) or adding 0.1% SDS to TBST wash buffers can reduce non-specific interactions.

If experiencing weak signals, several approaches can help. For Western blots, increase protein loading (50-100 μg total protein) or enrich your sample through immunoprecipitation before analysis . Optimize antibody concentration through titration experiments—start with the manufacturer's recommended dilution and test 2-fold dilutions above and below this concentration . Extended primary antibody incubation times (overnight at 4°C) can also enhance specific signal detection.

For immunohistochemistry and immunofluorescence applications, optimize antigen retrieval methods. Heat-induced epitope retrieval with citrate buffer (pH 6.0) or EDTA buffer (pH 9.0) often improves accessibility of PPP1R12A epitopes . Signal amplification systems like tyramide signal amplification can significantly enhance sensitivity for detecting low-abundance targets.

If phospho-specific antibodies show weak signals, consider using phosphatase inhibitors (sodium orthovanadate, sodium fluoride, β-glycerophosphate) during sample preparation to preserve phosphorylation status . For cell culture experiments, treatments that enhance the specific phosphorylation (e.g., calyculin A for certain sites) prior to sample collection can increase detection of phosphorylated PPP1R12A.

Finally, for persistent problems, consider alternative antibody clones targeting different epitopes or from different manufacturers, as some epitopes may be masked or modified in your experimental system .

What are the optimal protocols for Western blot detection of PPP1R12A?

Successful Western blot detection of PPP1R12A requires careful optimization at multiple steps. Begin with sample preparation by extracting proteins using RIPA buffer supplemented with protease inhibitors (PMSF, aprotinin, leupeptin) and phosphatase inhibitors (sodium orthovanadate, sodium fluoride) if detecting phosphorylated forms . Sonication of samples can improve extraction of this cytoskeletal-associated protein.

For gel electrophoresis, use 8% SDS-PAGE gels to properly resolve the 115.3 kDa PPP1R12A protein . Load adequate protein (30-50 μg of total protein from cell lysates) to ensure detection. After electrophoresis, transfer proteins to PVDF membranes rather than nitrocellulose for better protein retention during the long transfer times needed for high molecular weight proteins (transfer at 30V overnight at 4°C or 100V for 2 hours with cooling).

When blocking, use 5% non-fat dry milk in TBST for detection of total PPP1R12A, but switch to 5% BSA in TBST for phospho-specific antibodies, as milk contains phospho-proteins that may interfere with phospho-antibody binding . Incubate primary antibodies at optimal dilutions (typically 1:500 to 1:2000) overnight at 4°C with gentle rocking .

For detection, HRP-conjugated secondary antibodies with enhanced chemiluminescence (ECL) systems provide sensitive detection. For phosphorylated forms that may be less abundant, consider using more sensitive ECL substrates or fluorescently-labeled secondary antibodies with digital imaging systems for better quantification .

For troubleshooting, note that PPP1R12A can sometimes appear as multiple bands due to its various isoforms and post-translational modifications . When analyzing phosphorylation states, always include controls such as phosphatase-treated samples to confirm specificity of phospho-antibodies .

How should I optimize immunofluorescence protocols for PPP1R12A detection?

Optimizing immunofluorescence for PPP1R12A detection requires careful attention to fixation, permeabilization, and antibody incubation conditions. Begin with fixation—paraformaldehyde (4% for 15-20 minutes at room temperature) preserves PPP1R12A antigenicity while maintaining cellular structure . For certain epitopes, particularly phosphorylated forms, methanol fixation (-20°C for 10 minutes) may provide better results by exposing epitopes while simultaneously permeabilizing cells.

Permeabilization is critical for accessing the cytoplasmic PPP1R12A. Use 0.15-0.2% Triton X-100 in PBS for 10 minutes at room temperature, which has been validated for PPP1R12A detection in A431 cells . For delicate samples, a milder detergent like 0.1% saponin may preserve morphology better while still allowing antibody access.

Blocking should be performed with 5-10% normal serum (from the species in which the secondary antibody was raised) supplemented with 1% BSA in PBS for 30-60 minutes at room temperature . This reduces background staining while preserving specific signals.

Primary antibody incubation should be optimized—start with the manufacturer's recommended concentration (typically 5-10 μg/ml for purified antibodies) and incubate for 1-2 hours at room temperature or overnight at 4°C . For phospho-specific antibodies, add phosphatase inhibitors to all buffers to preserve phosphorylation status.

For visualization, use fluorophore-conjugated secondary antibodies matched to your microscopy setup. Typically, a 1:200 to 1:500 dilution of secondary antibody (2 μg/ml) for 1 hour at room temperature is effective . Include DAPI (1 μg/ml) for nuclear counterstaining to help define cellular boundaries and provide context for the cytoplasmic PPP1R12A signal.

Always include negative controls using isotype-matched immunoglobulins at the same concentration as your primary antibody. For example, unimmunized goat IgG (10 μg/ml) has been validated as an appropriate negative control for goat anti-PPP1R12A antibodies .

What are the key considerations for analyzing PPP1R12A phosphorylation states?

Analyzing PPP1R12A phosphorylation states presents unique challenges requiring specialized approaches. First, understand the critical phosphorylation sites—Thr696, Thr853, and Ser507 are key regulatory sites with distinct functional implications . Each site may be phosphorylated by different kinases and under different conditions, necessitating site-specific analysis.

Sample preparation is crucial—phosphorylation states are highly labile, so rapid sample processing with phosphatase inhibitors is essential. Use a lysis buffer containing sodium orthovanadate (1-2 mM), sodium fluoride (10 mM), β-glycerophosphate (5-10 mM), and EDTA (1-2 mM) to preserve phosphorylation status . Process samples on ice and minimize the time between sample collection and analysis.

When selecting antibodies, use phospho-site-specific antibodies validated for your application (WB, IHC, IF) and species . These antibodies should demonstrate specificity through phosphatase treatment controls. For comprehensive analysis, parallel detection of total PPP1R12A and phosphorylated forms is recommended to calculate the proportion of phosphorylated protein.

For experimental design, include appropriate controls: phosphatase-treated samples as negative controls and samples treated with phosphorylation-enhancing agents as positive controls. For example, calyculin A treatment increases phosphorylation at multiple sites and serves as an effective positive control .

Quantification methods should be carefully selected—for Western blots, use digital imaging and analysis software that can accurately measure signal intensity. Normalization to total PPP1R12A levels is essential for meaningful comparisons. For microscopy-based methods, quantitative image analysis with appropriate background correction is necessary for reliable results.

Finally, biological interpretation requires understanding the context-dependent effects of phosphorylation. For instance, phosphorylation at Thr696 inhibits myosin phosphatase activity, while other sites may have different functional consequences . These distinctions are critical for correctly interpreting your experimental findings in the context of cellular physiology.

How can PPP1R12A antibodies be used to investigate smooth muscle contractility mechanisms?

PPP1R12A antibodies serve as powerful tools for investigating smooth muscle contractility mechanisms through multiple experimental approaches. Begin with immunolocalization studies using phospho-specific antibodies (pThr696, pThr853) to visualize the spatial and temporal dynamics of PPP1R12A phosphorylation during contraction-relaxation cycles . This can be performed in fixed tissue sections or in cultured smooth muscle cells subjected to contractile agonists like phenylephrine, angiotensin II, or thromboxane analogs.

For biochemical analyses, use co-immunoprecipitation with PPP1R12A antibodies to isolate the myosin phosphatase complex and identify interaction partners under different contractile states . This approach can reveal how regulatory proteins like RhoA/ROCK, ZIPK, or ILK modulate myosin phosphatase activity through direct interactions or phosphorylation events.

Phosphorylation-state specific antibodies are particularly valuable for quantifying the ratio of phosphorylated to total PPP1R12A in response to various stimuli . By correlating this ratio with measurements of muscle tension in organ bath studies or traction force microscopy, researchers can establish direct relationships between PPP1R12A phosphorylation states and functional contractile responses.

In more sophisticated approaches, combine PPP1R12A antibodies with proximity ligation assays to visualize and quantify protein-protein interactions in situ . This technique can reveal how the spatial organization of signaling complexes containing PPP1R12A changes during contraction-relaxation cycles.

For real-time dynamics, consider using PPP1R12A antibody-based biosensors or FRET-based approaches after validating antibody specificity. These methods enable monitoring of PPP1R12A phosphorylation or conformational changes in live cells, providing unprecedented insights into the temporal aspects of myosin phosphatase regulation during smooth muscle contraction.

What approaches can be used to study PPP1R12A in cancer research and its potential tumor suppressor role?

For mechanistic studies, examine the PPP1R12A-merlin-CPI17 axis implicated in tumor suppression . Co-immunoprecipitation experiments using PPP1R12A antibodies can identify altered protein-protein interactions in cancer cells compared to normal counterparts. Parallel assessment of merlin phosphorylation status (particularly at Ser518) can reveal dysregulation of this pathway in cancer contexts.

Functional studies are essential—use phospho-specific antibodies to monitor PPP1R12A phosphorylation following manipulation of upstream regulators (like CPI17) or in response to oncogenic signaling activation . This approach can establish how cancer-associated signaling pathways impact PPP1R12A function and subsequently affect merlin phosphorylation and Ras activation.

For in vitro transformation assays, combine PPP1R12A antibodies with immunofluorescence to monitor changes in cytoskeletal organization and cell morphology following PPP1R12A knockdown or overexpression . This can provide visual evidence of the transformation phenotype associated with PPP1R12A dysfunction.

Advanced studies might employ tissue microarray analysis with PPP1R12A antibodies to correlate expression patterns with clinical outcomes across large patient cohorts. This approach can establish the prognostic significance of PPP1R12A expression or phosphorylation in specific cancer types.

Finally, therapeutic targeting studies might explore how modulation of PPP1R12A phosphorylation affects cancer cell proliferation, migration, and invasion. Antibodies specific to phosphorylated forms can serve as critical tools for monitoring the efficacy of compounds targeting kinases or phosphatases in this pathway .

How can I employ PPP1R12A antibodies in studies of cardiovascular disease mechanisms?

PPP1R12A antibodies offer valuable tools for investigating cardiovascular disease mechanisms, particularly those involving vascular smooth muscle dysfunction. Begin with immunohistochemical analysis of vascular specimens from normal and diseased vessels (atherosclerotic plaques, restenotic lesions, or aneurysms) using PPP1R12A antibodies to assess expression patterns and localization changes . Pay particular attention to the medial layer containing vascular smooth muscle cells (VSMCs).

For hypertension research, use phospho-specific antibodies (pThr696, pThr853) to quantify PPP1R12A phosphorylation states in resistance vessels from normotensive versus hypertensive models . This approach can reveal dysregulation of the myosin phosphatase regulatory pathway that contributes to increased vascular tone and blood pressure elevation.

In atherosclerosis studies, combine PPP1R12A immunostaining with markers of VSMC phenotype (contractile versus synthetic) to investigate how MYPT1 regulation correlates with VSMC phenotypic switching—a key process in atherosclerotic plaque development . This can be performed in tissue sections or in cultured VSMCs subjected to atherogenic stimuli like oxidized LDL or inflammatory cytokines.

For mechanistic studies of endothelial dysfunction, use co-immunoprecipitation with PPP1R12A antibodies to investigate how endothelial-derived vasoactive factors (NO, prostacyclin, endothelin) modulate the interaction between PPP1R12A and PP1C in adjacent VSMCs . This approach can reveal paracrine signaling mechanisms that regulate vascular tone.

In studies of vascular remodeling after injury, use PPP1R12A antibodies for immunofluorescence to track changes in expression and phosphorylation during the proliferative and migratory phases of VSMC response . This can provide insights into the molecular mechanisms underlying restenosis after angioplasty or stent placement.

Advanced applications might include phospho-proteomics approaches where PPP1R12A antibodies are used for enrichment of the phosphorylated protein before mass spectrometry analysis . This can reveal novel phosphorylation sites and their potential roles in cardiovascular pathophysiology.

How might PPP1R12A antibodies be utilized in stem cell and developmental biology research?

PPP1R12A antibodies present valuable opportunities for advancing stem cell and developmental biology research through multiple innovative approaches. For lineage tracing studies, combine PPP1R12A antibodies with markers of mesenchymal lineages (particularly smooth muscle) to track differentiation trajectories during embryonic development or stem cell differentiation in vitro . This approach can reveal when and where PPP1R12A expression is initiated during specification of contractile cell types.

In pluripotent stem cell differentiation protocols targeting smooth muscle or cardiac lineages, use PPP1R12A antibodies for quality control and maturation assessment . The progressive expression and appropriate subcellular localization of PPP1R12A can serve as indicators of functional maturation in these contractile lineages.

For mechanistic studies, investigate how PPP1R12A phosphorylation states change during critical developmental transitions or differentiation events . This can be accomplished using phospho-specific antibodies to track the activation state of myosin phosphatase during morphogenetic movements that require precisely controlled contractility.

In organoid systems modeling tissue development, employ immunofluorescence with PPP1R12A antibodies to visualize the organization of contractile elements and their regulation during self-organization processes . This approach is particularly valuable for intestinal, vascular, or airway organoids where smooth muscle components play critical functional roles.

For studies of developmental disorders associated with PPP1R12A mutations (such as Genitourinary And/Or Brain Malformation Syndrome), use antibodies to assess how pathogenic variants affect protein expression, localization, or phosphorylation in patient-derived cells or model systems . This can provide insights into the molecular mechanisms underlying developmental abnormalities.

Advanced single-cell approaches might combine flow cytometry using PPP1R12A antibodies with transcriptomic analysis to identify and characterize rare contractile progenitor populations during development . This integrated approach can reveal previously unrecognized heterogeneity in developing tissues with contractile elements.

What novel techniques are emerging for studying PPP1R12A protein-protein interactions?

Emerging techniques for studying PPP1R12A protein-protein interactions offer unprecedented insights into the functional complexes formed by this regulatory protein. Proximity-dependent biotin labeling (BioID or TurboID) represents a powerful approach—by fusing a biotin ligase to PPP1R12A, researchers can identify proteins that come into close proximity with PPP1R12A in living cells . After biotin labeling, PPP1R12A antibodies can be used to confirm the expression and localization of the fusion protein, while streptavidin-based purification isolates the biotinylated interaction partners for proteomic analysis.

CRISPR-based techniques offer another frontier—CRISPR knock-in of tags (like HaloTag or SNAP-tag) at the endogenous PPP1R12A locus allows for live-cell visualization of protein-protein interactions when combined with differentially labeled potential interaction partners . While not directly using antibodies, validation of these systems often requires antibody-based confirmation of proper tagging and expression.

For studying dynamic interactions in real-time, Förster Resonance Energy Transfer (FRET) or Bioluminescence Resonance Energy Transfer (BRET) between PPP1R12A and potential binding partners can reveal interaction kinetics in response to stimuli . Antibodies play crucial roles in validating these systems by confirming expression levels and localization patterns of the fusion proteins.

Advanced imaging techniques like super-resolution microscopy (STORM, PALM) combined with PPP1R12A antibodies can visualize the nanoscale organization of myosin phosphatase complexes at unprecedented resolution . This approach reveals spatial organization that may be critical for understanding how PPP1R12A interactions are regulated in specific subcellular domains.

Hydrogen-deuterium exchange mass spectrometry (HDX-MS) combined with immunoprecipitation using PPP1R12A antibodies can identify conformational changes that occur upon binding to different partners or following phosphorylation events . This technique provides structural insights that are difficult to obtain through traditional structural biology approaches for dynamic regulatory complexes.

Finally, mass spectrometry-based cross-linking (XL-MS) of complexes isolated using PPP1R12A antibodies can map the specific residues involved in protein-protein interactions, providing detailed molecular information about interface regions and how they may be altered by post-translational modifications or disease-associated mutations .

How will advances in antibody technology impact future PPP1R12A research?

Advances in antibody technology are poised to revolutionize PPP1R12A research through multiple innovations. Recombinant antibody development using phage display or yeast display libraries allows the generation of highly specific anti-PPP1R12A antibodies with reduced batch-to-batch variability compared to traditional polyclonal antibodies . These technologies enable epitope-specific antibodies targeting previously challenging regions of PPP1R12A.

Single-domain antibodies (nanobodies) derived from camelid immunoglobulins offer exciting possibilities for PPP1R12A research due to their small size (approximately 15 kDa) and ability to access epitopes that conventional antibodies cannot reach . Their reduced size makes them particularly valuable for super-resolution microscopy applications studying PPP1R12A in complex cytoskeletal structures.

Intrabodies—antibodies designed to function within living cells—represent another frontier. By expressing anti-PPP1R12A intrabodies fused to degradation signals or localization sequences, researchers can achieve acute inhibition or relocalization of PPP1R12A in specific cellular compartments . This approach enables temporal control over PPP1R12A function not possible with genetic approaches like CRISPR knockout.

Antibody-based biosensors for detecting PPP1R12A phosphorylation states in living cells will transform our understanding of dynamic regulation. These might utilize Förster resonance energy transfer (FRET) principles, with phospho-specific anti-PPP1R12A antibody fragments that change conformation upon binding to phosphorylated epitopes, generating measurable FRET signals .

Multiplexed antibody-based imaging techniques like multiplexed ion beam imaging (MIBI) or co-detection by indexing (CODEX) will enable simultaneous visualization of PPP1R12A along with dozens of other proteins in the same tissue section . This approach will reveal complex regulatory networks and heterogeneity across cells within tissues that current methods cannot resolve.

Finally, antibody-drug conjugates might be explored for therapeutic targeting in conditions where PPP1R12A dysregulation contributes to pathology. While primarily developed for cancer therapy, this concept could be adapted to deliver pathway modulators specifically to cells expressing aberrant levels or forms of PPP1R12A in diseases like hypertension or fibrotic disorders .